| Market Cap | 80.19M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -37.28M | Forward P/E | -2.54 | EPS next Y | 18.20% | 50D Avg Chg | -16.00% |
| Sales | 31.41k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | 5.07 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | 1.50 | Quick Ratio | 0.17 | Shares Outstanding | 76.91M | 52W Low Chg | 41.00% |
| Insider Own | 11.22% | ROA | -92.94% | Shares Float | 49.30M | Beta | 1.74 |
| Inst Own | 15.26% | ROE | -914.66% | Shares Shorted/Prior | 3.31M/3.03M | Price | 2.11 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 492,187 | Target Price | 10.83 |
| Oper. Margin | -51,661.19% | Earnings Date | Nov 11 | Volume | 113,675 | Change | 0.96% |
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
| HC Wainwright & Co. | Buy | Aug 13, 24 |
| HC Wainwright & Co. | Buy | Jul 24, 24 |
| HC Wainwright & Co. | Buy | May 16, 24 |
| HC Wainwright & Co. | Buy | Mar 19, 24 |
| HC Wainwright & Co. | Buy | Mar 6, 24 |
| HC Wainwright & Co. | Buy | Nov 14, 23 |
| William Blair | Outperform | Nov 1, 23 |
| Brookline Capital | Buy | Oct 17, 23 |
| HC Wainwright & Co. | Buy | Aug 18, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Strahlman Ellen R | Director Director | Sep 29 | Buy | 1.68 | 4,820 | 8,098 | 75,113 | 10/02/23 |
| Rowe Michael M | Chief Executive Offi.. Chief Executive Officer | Sep 15 | Buy | 1.71 | 2,537 | 4,338 | 28,037 | 09/19/23 |
| GANDOLFO JOHN P | Chief Financial Offi.. Chief Financial Officer | May 31 | Buy | 2.79 | 2,000 | 5,580 | 8,000 | 05/31/23 |
| Kern Bren | Chief Operating Offi.. Chief Operating Officer | May 26 | Buy | 2.73 | 2,500 | 6,825 | 2,500 | 05/31/23 |
| MATHER CHARLES E IV | Director Director | May 26 | Buy | 2.4899 | 3,000 | 7,470 | 77,544 | 05/30/23 |
| Grant Stuart M. | Director Director | May 25 | Buy | 2.65 | 88,247 | 233,855 | 5,194,998 | 05/26/23 |
| MATHER CHARLES E IV | Director Director | May 15 | Buy | 3.39 | 4,000 | 13,560 | 74,544 | 05/16/23 |
| Ianchulev Tsontcho | Director Director | May 01 | Sell | 5.50 | 90,000 | 495,000 | 331,211 | 05/02/23 |
| Rowe Michael M | Chief Executive Offi.. Chief Executive Officer | May 01 | Option | 2.72 | 10,000 | 27,200 | 25,500 | 05/01/23 |
| Ianchulev Tsontcho | Director Director | Apr 14 | Sell | 4.50 | 40,000 | 180,000 | 481,211 | 04/17/23 |
| Ianchulev Tsontcho | Director Director | Apr 11 | Sell | 4 | 40,000 | 160,000 | 521,211 | 04/12/23 |
| Ianchulev Tsontcho | Director Director | Mar 31 | Sell | 3.50 | 40,000 | 140,000 | 561,211 | 04/03/23 |
| Rowe Michael M | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Dec 30 | Buy | 1.54 | 10,000 | 15,400 | 15,500 | 01/03/23 |
| Grant Stuart M. | Director Director | Dec 30 | Buy | 1.50 | 21,753 | 32,630 | 5,106,751 | 01/03/23 |
| Strahlman Ellen R | Director Director | Aug 29 | Buy | 1.61 | 21,361 | 34,391 | 43,052 | 08/31/22 |
| Strahlman Ellen R | Director Director | Aug 24 | Buy | 1.5853 | 1,504 | 2,384 | 21,691 | 08/25/22 |
| Grant Stuart M. | Director Director | Jun 21 | Buy | 1.65 | 100,000 | 165,000 | 5,084,998 | 06/23/22 |
| LEE KENNETH B JR | Director Director | May 19 | Buy | 2.20 | 10,000 | 22,000 | 42,322 | 05/23/22 |
| MATHER CHARLES E IV | Director Director | May 18 | Buy | 2.0331 | 7,000 | 14,232 | 48,322 | 05/19/22 |
| Grant Stuart M. | Director Director | May 10 | Buy | 1.97 | 75,000 | 147,750 | 4,984,998 | 05/12/22 |
| Grant Stuart M. | Director Director | May 04 | Buy | 2.26 | 50,000 | 113,000 | 4,935,924 | 05/05/22 |
| Grant Stuart M. | Director Director | Apr 21 | Buy | 2.57 | 58,800 | 151,116 | 4,885,924 | 04/25/22 |
| MATHER CHARLES E IV | Director Director | Mar 31 | Buy | 3.115 | 4,000 | 12,460 | 41,322 | 03/31/22 |
| Grant Stuart M. | Director Director | Feb 07 | Buy | 2.97 | 36,030 | 107,009 | 4,775,124 | 02/08/22 |
| Grant Stuart M. | Director Director | Oct 29 | Buy | 3.75 | 15,505 | 58,144 | 4,539,094 | 11/02/21 |
| Grant Stuart M. | Director Director | Oct 25 | Buy | 4 | 133,806 | 535,224 | 4,523,589 | 10/27/21 |